About Foamix Pharmaceuticals
Foamix Pharmaceuticals Ltd. is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing its minocycline foam for the treatment of acne, rosacea, impetigo and other skin conditions. The Company operates in the segment of development and commercialization of foam-based formulations. The Company develops FMX101, FMX102, FMX103 and FDX104 using its technology, which includes foam-based platforms. The Company's lead product candidate FMX101, is a novel topical foam formulation of the antibiotic minocycline. The Company develops FMX102, a minocycline foam product candidate for the treatment of impetigo, including cases of impetigo caused by methicillin-resistant staphylococcus aureus (MRSA). It is also developing FMX103, minocycline foam for rosacea. FDX104 is a topical foam formulation of the antibiotic doxycycline for the treatment of severe acne-like rashes induced by chemotherapy. It completed a Phase II clinical trial for FMX102.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: FOMX
- Previous Close: $10.24
- 50 Day Moving Average: $10.41
- 200 Day Moving Average: $9.50
- 52-Week Range: $5.48 - $11.27
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -6.97
- P/E Growth: 0.00
- Market Cap: $374.77M
- Outstanding Shares: 36,599,000
- Beta: 1.62
- Net Margins: -554.14%
- Return on Equity: -22.55%
- Return on Assets: -21.59%
Companies Related to Foamix Pharmaceuticals:
- Current Ratio: 18.90%
- Quick Ratio: 18.90%
What is Foamix Pharmaceuticals' stock symbol?
Foamix Pharmaceuticals trades on the NASDAQ under the ticker symbol "FOMX."
Where is Foamix Pharmaceuticals' stock going? Where will Foamix Pharmaceuticals' stock price be in 2017?
2 equities research analysts have issued 1 year target prices for Foamix Pharmaceuticals' stock. Their forecasts range from $20.00 to $22.00. On average, they expect Foamix Pharmaceuticals' stock price to reach $21.00 in the next year.
When will Foamix Pharmaceuticals announce their earnings?
Foamix Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, March, 1st 2017.
Who owns Foamix Pharmaceuticals stock?
Foamix Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Franklin Resources Inc. (4.21%), Menora Mivtachim Holdings LTD. (3.69%), Perceptive Advisors LLC (3.61%), Deerfield Management Co. (3.37%), Vivo Capital LLC (2.34%) and Alyeska Investment Group L.P. (1.79%).
Who sold Foamix Pharmaceuticals stock? Who is selling Foamix Pharmaceuticals stock?
Foamix Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including J. Goldman & Co LP, Folger Hill Asset Management LP, Deerfield Management Co., Menta Capital LLC and Van ECK Associates Corp.
Who bought Foamix Pharmaceuticals stock? Who is buying Foamix Pharmaceuticals stock?
Foamix Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Trexquant Investment LP and Alyeska Investment Group L.P..
How do I buy Foamix Pharmaceuticals stock?
Shares of Foamix Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Foamix Pharmaceuticals stock cost?
One share of Foamix Pharmaceuticals stock can currently be purchased for approximately $10.24.